(NewsDirect)
While stem celltherapy has always been a more controversial topic, as the generalpublic has gained more knowledge on the practice and inducedpluripotent stem (iPS) cells have gained traction in place ofhuman embryonic stem (hES) cells, the conversation has shifted morefrom the ethical concerns to the logistical concerns.
Governments, medicalfacilities, and patients are concerned over the economical viabilityand clinical efficacy of regenerative medicine and stem cell research.Today, sixof the seven leading causes of death in America arenon-communicable diseases and regenerative medicine is a promisingbranch of science to lead the fight.
Arecent study conducted in 2021 , highlighted thecost-effectiveness of regenerative medicine. Looking at a handful ofstem cell therapies, the study showed that regenerative medicine islikely to be more impactful in cost-effectiveness compared to otherconventional health technologies. The study also noted that for stemcell treatment of scoliosis, the level of cost-effectiveness wasacceptable to policymakers and healthcare purchasers.
It is also important tonote that the best treatment for patients are ones that minimize painwhile avoiding dangerous procedures like surgeries. As such,autologous cell therapy falls in this category because the treatmentcomes from the patient’s body, and the risks are significantlyminimized.
Withthe treatment risks minimized, the question of clinical efficacy stillremains. How successful are stem cell therapies when compared totraditional treatments? Studies are showing promising results for stemcell therapies when it comes to obesity-related diseases and chronicback pain, among other non-communicable diseases.
Current non-operativeand surgical treatments for discongeniclow back pain are leaving patients dissatisfied, whereas, stemcell regenerative therapy has shown strong results in restoringdisc’s cellularity and decreasing inflammatory response in patients.With chronic low back pain impacting approximately 632 million peopleworldwide and as high as 68% of adults over the age of 60, finding acure that minimizes risk and maximizes results would revolutionizetreatment.
Stem cells have also shown significanttherapeutic potential in patients with diabetes , one of themost prevalent and deadly diseases globally. From stem cell therapiesbeing able to regenerate into insulin-producing cells to therapiesthat can stimulate metabolism, the field is ripe with opportunitiesfor patients.
BioRestorative Is Making Advancements In ChronicPain and Diabetes
BioRestorative Therapies Inc. (NASDAQ: BRTX)(“BioRestorative”) is working on products that may be solutions inmultibillion-dollar fields. Trials suggest that BRTX-100 maysignificantly reduce back pain and increase function in patients.There are over 60 million suffering from chronic back pain in the U.S. While thecurrent product specifically treats disc degeneration, BioRestorativebelieves it shows signs of a broad range of applications within theentire musculoskeletal system (Hips, knees, shoulders andextremities).
BioRestorative Therapies prides itself on doing thingscorrectly. Its BRTX100 product for back pain goes far beyond theall-too-common clinical practice of harvesting cells and reintroducingthem to the patient without proper modification.
Instead, BioRestorativeTherapies expands and cultures the cells using a proprietary hypoxictreatment, where a low-oxygen environment transitions the cells toexpress a more potent therapeutic benefit. They also combine thesecells with the patient’s own platelet lysate which acts as afertilizer to the cells and helps deliver a more survivable cell intothe harsh environment of the disc. These cells not only have a greatersurvival rate but show increase in anti-inflammatory properties,increased circulation and enhancement of remodeling the extracellularmatrix of the disc. It also only uses autologous cells for thistreatment. Autologous cells come from the patient's own body andhave little to no risk that the body will reject them, increasingprobability of optimal results within the biological micro environmentmatching process
BRTX’s Brown Fat Program, Thermostem, has highly promisingresults in the treatment of obesity and related metabolic diseases.Obesity affects over 40% ofAmericans , and BioRestorative is developing a novel stem-cell population — brown adipose tissue — that showssigns of stimulating metabolism and reducing excess fat.
Close cooperation withthe FDA is also important to BioRestorative, as the external oversightserves as a guarantor of product quality and efficacy. FDA approvalalso helps drive down the cost of these therapies for patients, asinsurance companies are more willing to partially or fully cover thecost of FDA-approved medicines.
Tolearn more about BioRestorative, visit its website .
BioRestorative Therapies was founded by scientists andresearchers committed to developing stem cell therapies to addressunmet needs in patients with highly prevalent conditions.Our advancesin stem cell biology and delivery protocols harbor great promise inconditioning our bodies’ own regenerative potential to treat majordiseases more effectively than current interventions.Today,BioRestorative is actively developing programs that aim todramatically increase quality of care for both (i) chronic back paincaused by disc degeneration, as well as (ii) metabolic disordersincluding obesity and diabetes.
This post contains sponsoredadvertising content. This content is for informational purposes onlyand is not intended to be investing advice.
ContactDetails
Investor Relations
CompanyWebsite
https://www.biorestorative.com/
Copyright (c) 2022 TheNewswire - All rights reserved.